Proton pump inhibitors for upper gastrointestinal bleeding

Omar Kherad; Sophie Restellini; Myriam Martel; Alan Barkun

doi:10.1016/j.bpg.2019.04.002

Proton pump inhibitors for upper gastrointestinal bleeding

Best Pract Res Clin Gastroenterol. 2019 Oct-Dec:42-43:101609. doi: 10.1016/j.bpg.2019.04.002. Epub 2019 Apr 17.

Authors

Omar Kherad¹, Sophie Restellini², Myriam Martel³, Alan Barkun⁴

Affiliations

¹ Internal Medicine Department, La Tour Hospital and University of Geneva, Switzerland. Electronic address: omar.kherad@latour.ch.
² Department of Specialties, Division of Gastro-enterology and Hepatology, Geneva University Hospital, Switzerland; Division of Gastroenterology, McGill University, Montreal, Canada. Electronic address: sophie.restellini@hcuge.ch.
³ Division of Gastroenterology, McGill University, Montreal, Canada.
⁴ Division of Gastroenterology, McGill University, Montreal, Canada. Electronic address: alan.barkun@muhc.mcgill.ca.

PMID: 31785730
DOI: 10.1016/j.bpg.2019.04.002

Abstract

Acute upper gastrointestinal bleeding (UGIB) remains a public health burden with a persistent high mortality despite advances in modern day management. Proton pump inhibitors (PPI) as medical therapy is an attractive adjuvant to endoscopic treatment in UGIB but the method and dose of PPI therapy remains controversial. This chapter aims to describe the current evidence addressing acute PPI use in the management of UGIB. It will explore the evidence behind the timing, the dosage and the mode of administration of PPI during initial UGIB management, prior to and immediately following endoscopy, as well as in the short-term following discharge.

Keywords: Endoscopy; Hemorrhage; Proton pump inhibitor; Upper gastrointestinal bleeding.

Publication types

Review

MeSH terms

Gastrointestinal Hemorrhage / drug therapy*
Humans
Proton Pump Inhibitors / pharmacology
Proton Pump Inhibitors / therapeutic use*

Substances

Proton Pump Inhibitors